JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Travere Therapeutics (NASDAQ:TVTX) and raises the price target from $19 to $20.
August 13, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Travere Therapeutics and raises the price target from $19 to $20.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to boost investor confidence in Travere Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100